Research and development
Webinars and whitepapers
- Previous
- Next
Research and development
ArticleAI builds dual-action cancer drug targeting PKMYT1
New research published in Nature Communications shows how generative AI can be used to design complex dual-action cancer drug candidates. Insilico Medicine has developed a PKMYT1 degrader that both eliminates the target protein and blocks its activity, demonstrating the growing role of AI in advanced drug discovery.
ArticleAI to antibody in days: breaking the wet lab bottleneck via high-throughput integration
AI is accelerating drug discovery at an unprecedented pace. Thousands of antibody candidates can now be designed in silico within hours. The challenge now is keeping experimental workflows fast enough to keep up. High-throughput expression and integrated developability assessment are making it possible to move from sequence to data in days.
ArticleImproving selectivity in antibody–drug conjugates
Promatix Biosciences is developing a new generation of bispecific antibody–drug conjugates using proprietary membrane proteomics data to identify highly selective target pairings. CEO Dr Michael Hunter explains how the company’s TXPro database enables discovery of previously unexplored tumour biology to improve therapeutic index and reduce on-target/off-tumour toxicities in solid tumours.
ArticleFrom fragments to maps: scaling drug–target interaction data
Most drug–target data were never designed to be compared at scale. Pharmome mapping takes a different approach, building a shared dataset intended to support more predictable discovery.
Join now
Unlock exclusive industry insights
- Bookmark articles and resources to access anytime
- Enjoy free access to industry leading resources, webinars and insights
- Stay informed with the latest news and breakthroughs
- Receive updates and recommendations tailored to your research interests
ReportCRISPR & Genomics: Turning Data into Confident Drug Discovery Decisions
Early drug discovery has no shortage of genomic data, but confidence remains scarce. This report examines how CRISPR, functional genomics and human-relevant models are being applied to determine which signals matter, how they influence disease biology and which targets and strategies are worth pursuing.
InterviewComputational design drives new generation of synthetic promoters
Designing gene control from scratch is becoming possible. SynGenSys is using computational design to create synthetic promoters for advanced therapies.
InterviewPhysics-based modelling offers a new way to study drug targets
Australian start-up OmnigeniQ has demonstrated what it describes as the first deterministic, physics-based computation of a human protein in its native state.
ArticleAnticipating adaptation: understanding and overcoming cancer drug resistance
Neil Bhowmick explores how understanding the mechanisms of cancer drug resistance has reframed our approach to treatment, revealing containment and control as realistic goals for therapeutic strategies.
ArticleKMA and LMA antigens emerge as high value targets for plasma cell dyscrasia treatment
Research published in Clinical Lymphoma, Myeloma and Leukemia identifies Kappa Myeloma Antigen and Lambda Myeloma Antigen as highly selective immunotherapy targets across plasma cell dyscrasias.
ArticleWhy NMDA receptor modulation remains central to next-generation depression therapies
A key player in brain communication and mood regulation, the pharmaceutical industry views the NMDAR as the central pillar for next-generation therapies for depression. Dirk Beher from FundaMental Pharma reveals new strategies for targeting this important receptor.
ArticleDesigning targeted assays for clinical success from the start
Why do some targeted assays move smoothly from discovery to clinical practice while others stall? The answer often lies in the earliest design decisions, where choices about samples, platforms and data determine what is possible later.
ArticleDiscovery is changing – and automation leads the way
Automation is helping drug discovery teams screen faster, cut costs and run complex assays at scale – but its real value lies in what happens next.
ArticleWorld ADC 2026: where antibody-drug conjugates are heading
At World ADC London 2026, experts highlighted how advances in payload design, targeting strategies and AI-driven discovery are changing antibody–drug conjugate development.
InterviewHow self-driving labs are changing drug development
Automation and artificial intelligence are changing how scientists design, test and refine new molecules. At the University of Toronto, Stuart R Green and the Acceleration Consortium are building a self-driving lab that could change the pace of early drug discovery.
ArticleInternational Women’s Day: digital pathology in early drug discovery
For International Women’s Day, Dr Amanda Hemmerich, Global Director of Digital Pathology & Innovation at IQVIA Laboratories, describes how digital pathology is being applied in early drug development and what it takes to build credibility in a multidisciplinary technical field.
ArticleHow brain donation is driving autism research
To study the biological underpinnings of autism, researchers must examine the human brain itself. This article explores how Autism BrainNet supports this work through coordinated tissue donation and preservation.
ArticlePreclinical takeaways from the World ADC Conference London
Experts from the World ADC Conference in London highlight how patient-centric, predictive preclinical tools and innovative ADC designs are improving safety, efficacy and clinical translation.
ArticleDrug discovery integration takes centre stage at SLAS Boston 2026
Drug discovery has no shortage of powerful technologies, but the challenge now is making them work together. At SLAS Boston 2026, researchers and technology developers revealed how laboratories are connecting the entire experimental pipeline.
ArticleMaking immunotherapy safer and more accessible through continuous digital monitoring
Immunotherapies such as CAR-T are extending survival, yet reliance on inpatient monitoring for cytokine release syndrome continues to restrict access. This article explores how continuous digital monitoring and AI-driven analysis could enable safer outpatient delivery and support more scalable immunotherapy adoption.
ArticleIntegrated proteo-transcriptomics reveals multiple therapeutic targets in Candida auris
Scientists at the Medical University of Vienna identify multiple mechanisms of multidrug resistance in Candida auris, revealing new therapeutic opportunities.